CLAIMS

1. A TEAD inhibitor or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, wherein the TEAD inhibitor or pharmaceutically acceptable salt thereof is to be administered on each of the first 3 days of a 7 day treatment cycle, and wherein the treatment comprises at least two treatment cycles.

2. Use of a TEAD inhibitor, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer in a subject in need thereof, wherein a therapeutically effective amount of the medicament is to be administered to the subject on each of the first 3 days of a 7 day treatment cycle, and wherein the treatment comprises at least two treatment cycles.

3. Use of a TEAD inhibitor, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the reduction of albuminuria and/or kidney toxicity in a subject undergoing treatment with a TEAD inhibitor or a pharmaceutically acceptable salt thereof, wherein a therapeutically effective amount of the medicament is to be administered to the subject on each of the first 3 days of a 7 day treatment cycle, and wherein the treatment comprises at least two treatment cycles.

4. The use according to claim 2 or claim 3, wherein the TEAD inhibitor is a YAP/TAZ – TEAD protein/protein interaction inhibitor or a pharmaceutically acceptable salt thereof.

5. The use according to claim 4, wherein the TEAD inhibitor or salt thereof is 4-((2S,4S)-5-Chloro-6-fluoro-2-phenyl-2-((S)-pyrrolidin-2-yl)-2,3-dihydrobenzofuran-4-yl)-5-fluoro-6-(2-hydroxyethoxy)-N-methylnicotinamide or a pharmaceutically acceptable salt thereof.

6. The use according to any one of claims 2 to 5, wherein the daily dose on each administration day is from 15 mg to 500 mg.

7. The use according to claim 6, wherein the daily dose on each administration day is from 15 mg to 100 mg.

8. The use according to claim 6, wherein the daily dose on each administration day is 15, 30, 45, 60, 75 mg, 90 mg or 100 mg.

9. The use according to any one of claims 2 to 8, wherein the cancer is a TEAD dependent cancer or is a solid tumor with NF2/LATS1/LATS2 mutations.

10. The use according to any one of claims 2 to 9, wherein the cancer is selected from breast cancer, lung cancer, ovarian cancer, kidney cancer, uterine cancer, colorectal cancer, mesothelioma, e.g. malignant pleural mesothelioma, pancreatic cancer, prostate cancer, gastric cancer, esophageal cancer, liver cancer, medullobastoma, head and neck cancer, sarcoma, epithelioid hemangioendothelioma, ependymal tumor and bone cancer, e.g. wherein the cancer is mesothelioma, e.g. wherein the cancer is malignant pleural mesothelioma.